Fixim

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fixim

Property Description
Active Ingredient Cefixime
Form Oral (Tablet, Oral Suspension)
Pharmacological Class Third-Generation Cephalosporin Antibiotic
General Use Treating susceptible bacterial infections
Origin Semi-synthetic compound

Fixim is a specific brand name for the prescription oral antibiotic whose active ingredient is cefixime. Its function is to eliminate bacterial infections susceptible to this compound. Fixim is available in various territories, often marketed by manufacturers focusing on accessibility and stability for outpatient care.

As a member of the third-generation cephalosporin class, Fixim provides systemic treatment. This classification is clinically recognized for its broad antibacterial spectrum, making it a reliable choice for infections like acute bronchitis or middle ear infections when caused by specific, targeted bacteria. The classification of cefixime as a third-generation agent indicates its broad spectrum of activity and clinical utility against a wide range of common bacterial pathogens.

Cefixime: Composition and Origin

The therapeutic efficacy of Fixim stems solely from its composition of the active substance, cefixime. This compound is a semi-synthetic substance, created through chemical modification of a naturally occurring antibiotic structure. This modification enhances its effectiveness and stability against bacterial defenses.

A distinctive feature of the Fixim brand is its common availability as both a film-coated tablet and a powder for oral suspension. The liquid form is often specifically formulated for ease of administration in younger patients, offering a convenient, flexible option for finishing the full course of treatment at home.

The general therapeutic purpose of this antibiotic class is to combat bacterial growth by interfering with the integrity of the bacterial cell wall. This mechanism establishes Fixim's primary therapeutic role in clearing systemic bacterial infections.

What side effects are possible with Fixim?

Possible side effects and safety information

The safety profile of Fixim, whose active substance is cefixime, is officially categorized by regulatory documents based on the body system affected and the frequency of occurrence. The most frequently observed events are concentrated in the gastrointestinal system.

Frequency-Classified Adverse Reactions

The official labeling organizes adverse reactions by frequency, with Diarrhoea classified as Very Common (ge10%). Other commonly documented effects (classified as Common) include nausea, abdominal pain, flatulence, and dyspepsia.

Effects classified as Uncommon (ge0.1% to <1%) often involve vomiting, headache, rash, and transient elevations in liver enzymes (AST/ALT). Rare occurrences are also documented.

System-Organ Class Examples of Documented Adverse Reactions
Gastrointestinal Diarrhoea, abdominal pain, nausea, vomiting
Hemic and Lymphatic Thrombocytopenia, Eosinophilia
Immune System Anaphylactic reactions, Angioedema
Skin Rash, Urticaria, Stevens-Johnson Syndrome (SJS)

Serious Adverse Reactions and Restrictions

Official labels detail serious, though less frequent, adverse reactions. These include potentially life-threatening conditions such as severe hypersensitivity reactions (anaphylaxis) and severe skin reactions (SCARs). The risk of Pseudomembranous Colitis (Clostridium difficile-Associated Diarrhoea) is also documented, with onset possible during or after treatment.

Fixim is contraindicated in individuals with a known allergy to cefixime or any other cephalosporin antibiotics. Specific safety considerations are noted for patients with impaired renal function due to the drug's primary elimination route, and caution is required for individuals with a history of gastrointestinal disease.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Fixim


Overdose Scope

Entity Description (Strictly Label-Based)
Documented overdose presentations Adverse effects observed at dose levels up to 2 g did not significantly differ from the adverse reactions reported during standard therapeutic use.
Physiological systems affected (as stated in label) Central Nervous System (CNS) effects are a documented system of concern.
Dose-related or exposure-related factors (if applicable) High systemic drug concentrations resulting from unadjusted dosing in patients with impaired renal function elevate the risk of severe CNS complications.
Population-specific overdose notes (if applicable) Patients with existing renal impairment are specifically documented to be at greater risk for neurological complications, including seizures.
Emergency-response statements (as written in official documents) For life-threatening events, such as severe hypersensitivity or anaphylactic reactions, immediate drug discontinuation and the initiation of appropriate emergency measures are mandated.
When immediate medical help is required (label-derived phrasing only) Urgent medical attention must be sought immediately for symptoms indicating severe, life-threatening outcomes, including seizures or severe persistent diarrhea suggestive of pseudo-membranous colitis.

Overdose Classifications (High-Level)

Classification Description (Strictly Label-Based)
Severity classification (as defined in official documents) Overdose management focuses on symptomatic and supportive treatment of severe neurological and hypersensitivity events.
Regulatory basis (EMA / FDA / etc.) Information is based on official regulatory prescribing information (e.g., FDA, EMA SmPC).
Overdose-context constraints (as defined in official documents) No specific antidote exists. Cefixime is not removed in significant quantities by hemodialysis or peritoneal dialysis.

Resulting Overdose Structure

Official overdose statements:

  • Overdose manifestations are generally consistent with known adverse effects, but the risk of seizures and encephalopathy is specifically noted, particularly when renal function is impaired.
  • Treatment is limited to symptomatic and supportive care, as no specific antidote is known.
  • The drug is not significantly removed by dialysis.

Connection to the overall overdose profile (2–4 sentences): The official regulatory profile defines overdose primarily by the potential for serious neurological and hypersensitivity events that demand immediate emergency medical intervention. The documented limitations of treatment clarify the supportive nature of management and the need for continuous observation. The profile explicitly notes the heightened risk of CNS effects in patients with impaired renal function.

Therapeutic Uses of Fixim

Fixim is commonly used to manage infections caused by susceptible bacteria and is applied across domains where supportive symptom management is appropriate. The medication is considered relevant across clinical settings marked by heightened patient discomfort.

The medication is relevant for managing conditions that present with acute or disruptive episodes, including tonsillitis, pharyngitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated urinary tract infections (UTIs), uncomplicated gonorrhea, and serious systemic infections like Typhoid fever and Shigellosis. This contributes to improved comfort during periods of heightened symptoms and assists with managing symptoms related to systemic imbalance.


Quick Fact: Relief for Functional Strain

This medication is often used when symptoms create noticeable functional strain, such as the pain and frequency of urination (dysuria) associated with bladder infection. This supports assisting with maintaining functional stability and helps manage symptoms that interfere with daily functioning.

It is considered relevant for managing symptoms that interfere with daily comfort and is used across domains where short-term symptomatic assistance is appropriate. This application assists with maintaining stability and helps address the physiological stress linked to the infection, providing supportive relief when symptoms become more noticeable.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Who Can and Cannot Use Fixim?

This section outlines the official eligibility and non-eligibility requirements for Fixim (cefixime) based strictly on governmental regulatory documents.

Contraindicated Populations

Fixim is contraindicated for any patient with a known hypersensitivity (e.g., severe allergic reaction or anaphylaxis) to cefixime or to any other cephalosporin class antibacterial drug.

Age-Related Eligibility

The medicine is indicated for use in adults and pediatric patients six months of age and older. The efficacy and safety of Fixim have not been established in infants aged less than six months, making its use in this population generally restricted.

Condition-Specific Restrictions

  • Renal Impairment: Use is restricted and requires special consideration. A dose adjustment is mandatory for adult patients whose creatinine clearance is less than 60 mL/min.
  • Phenylketonuria (PKU): Patients with PKU should note that certain formulations, like the chewable tablets, contain phenylalanine.

Pregnancy and Lactation Status

  • Pregnancy: Fixim should be used during pregnancy only if clearly needed.
  • Lactation: For nursing mothers, regulatory documents state that consideration should be given to temporarily discontinuing nursing during treatment.

Overall Eligibility Constraints

To help maintain the effectiveness of the antibiotic and reduce the risk of developing drug-resistant bacteria, Fixim should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The interaction profile of Cefixime, the active ingredient in Fixim, is defined by specific pharmacokinetic and pharmacodynamic interactions documented in regulatory sources.

Property Description
Medicinal product categories with documented interactions: Anticoagulants, Uricosuric agents, Live bacterial vaccines, Calcium channel blockers, Anticonvulsants.
Specific interacting medicines: Warfarin, Probenecid, Carbamazepine, Nifedipine.

Official Interaction Statements

Co-administration of Cefixime with Probenecid results in a reduction in Cefixime's total clearance, leading to increased plasma concentrations due to competition for renal tubular clearance. Cefixime may enhance the effects of Warfarin and other coumarin-type anticoagulants, with official reports of increased prothrombin time. Elevated Carbamazepine levels have also been documented in postmarketing experience when co-administered. The calcium channel blocker Nifedipine may increase the bioavailability of Cefixime by up to 70%.

Interaction Restrictions and Compatibility

Cefixime is officially restricted for use with Live Bacterial Vaccines (such as Live Cholera or Live Typhoid Vaccine) due to the potential for interference with the immunization's therapeutic effect. Unlike some medications, Cefixime absorption is not significantly affected by co-administration with food or common antacids. Cefixime can cause a false-positive reaction for ketones and glucose in the urine when using specific testing methods.

Mechanism of Action

Targeted Inhibition of Bacterial Cell Wall Assembly

Cefixime, the active compound in Fixim, acts within the domain of bacterial structural synthesis by targeting specific enzymes known as Penicillin-Binding Proteins (PBPs), which are unique to bacteria. The drug irreversibly inhibits the transpeptidase activity of these enzymes, blocking the final step in the creation of the rigid peptidoglycan polymer that forms the bacterial cell wall. This molecular interference reduces the structural integrity of the peptidoglycan meshwork.


Autolytic Cascade and Pathogen Destruction

The loss of cell wall integrity activates an autolytic cascade within the bacterial cell, essentially initiating the cell's own self-destruction mechanisms. The inability of the structurally compromised cell to withstand internal osmotic pressure leads to osmotic lysis (rupture) of the pathogen. This bactericidal mechanism results in the osmotic lysis of susceptible bacterial cells, contributing to the reduction of the pathogenic load.

Dosage and Administration Information

Cefixime (Fixim) is administered exclusively by the oral route, available in multiple forms including tablets, capsules, and a powder for oral suspension. A standard procedural condition is that the tablet and capsule forms may be taken without regard to food. The oral suspension, however, requires reconstitution with water and must be shaken well before each measured dose.

Standard Dosing and Frequency

For adults, the typical daily dosage is 400 mg, which may be administered as a single dose once daily or divided into two 200 mg doses, 12 hours apart. For uncomplicated cervical or urethral gonorrhea, guidelines specify a single 400 mg oral dose. The standard duration of the treatment course generally ranges from 7 to 14 days; however, for infections caused by Streptococcus pyogenes, the regimen must be maintained for a minimum of 10 days.

Population-Specific Adjustments

Dose modification is a requirement for patients with documented renal impairment, specifically those with a creatinine clearance below 60 mL/min. For pediatric patients six months of age and older, the dose is calculated based on body weight at 8 mg/kg/day, administered once daily or divided every 12 hours. A key administration principle is that tablets and capsules should not be substituted for the oral suspension when treating acute otitis media.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fixim (Cefixime)

The research evidence for Fixim (cefixime) is primarily derived from clinical trials, including randomized controlled trials (RCTs) and multicenter studies, and are part of the evidence base utilized by official health authorities. These studies focus on documenting how patient symptoms and the presence of bacteria changed over short, defined periods. The findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.


Evidence for Use in Acute Otitis Media

Research involving cefixime for middle ear infections in children was primarily conducted using Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and measured two key outcomes: the change in outcomes related to physical discomfort (such as ear pain and fever) and the rate of bacteriologic eradication (clearance of the targeted pathogen).

Findings describe patterns observed in the studies related to the short-term clearance of infection and the rate at which clinical signs changed or improved. Some trials compared cefixime against other oral antibiotics, and reported measurements of outcomes for the study populations. However, the evidence remains limited and heterogeneous in terms of how specific symptoms are measured across older studies.


Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

For uncomplicated urinary tract infections, the research base includes both RCTs and various observational cohort studies. These studies focused on patient outcomes capturing phases of heightened symptom activity, such as the pain and frequency of urination, and microbial outcomes, defined by the documented clearance of bacteria from the urine.

Because bacterial resistance patterns are always evolving, the existing research may provide limited insight into the medication's performance against certain highly resistant bacterial strains, and findings in some studies were not uniform.


Research Gaps and Unanswered Questions

Clinical trials for antibiotics are typically designed to assess short-term outcomes. For Fixim, follow-up durations were limited to immediate post-treatment assessments. Therefore, there is limited information for long-term outcomes that would characterize the medication's impact on the overall trajectory of recurrent infections or the durability of the response over many months or years. Additionally, the evidence base includes extensive data for pediatric patients, but data for older adults with comorbidities remain insufficient.

Key Studies & References Cefixime: DailyMed Drug Label - U.S. National Library of Medicine

Frequently Asked Questions (FAQ)

Common questions about Fixim (FAQ)


Q: How long does it usually take to feel the effects of Fixim?

A: Official information indicates that improvement in symptoms is commonly observed during the first few days of treatment with this medication. Regulatory guidance emphasizes the importance of completing the full prescribed course, even if improvement is noted quickly.

Q: What are the most commonly reported side effects for Fixim?

A: According to the official product information, the most frequently reported adverse events are concentrated in the gastrointestinal system. These effects often include diarrhoea (up to 16% in studies), nausea, loose stools, abdominal pain, and vomiting.

Q: Can I drink alcohol while using Fixim?

A: Regulatory documents do not typically specify a major contraindication for moderate alcohol consumption while taking this medication. However, the potential for central nervous system side effects, such as dizziness or headache, may be increased when combined with alcohol, so it is important to note the potential for these effects.

Q: What is the typical duration of treatment with Fixim?

A: The standard course of treatment with this medication generally ranges from 7 to 14 days. Official guidelines state that for infections caused by Streptococcus pyogenes (like strep throat), the regimen must be maintained for a minimum of 10 days.

Q: What happens if I miss a dose of Fixim?

A: Regulatory guidance describes the procedure for a missed dose as taking it when remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped. It is noted that extra medicine should not be taken to compensate.

Q: What should I do if I accidentally take two doses close together?

A: In cases of suspected overdose, seeking medical attention is specified. Regulatory information notes that gastric lavage (stomach pumping) may be indicated in these situations, as there is no specific antidote, and dialysis procedures do not remove significant amounts of the drug from the body.

Q: Can Fixim be crushed or split if I have trouble swallowing pills?

A: The film-coated tablet formulation has a score line and may be split if a half-dose is required as directed by a healthcare provider. If you are taking the chewable tablets, official guidance states these should be completely chewed, or they may be crushed if swallowing is difficult.

Q: How is Fixim absorbed by the body?

A: When taken by mouth, approximately 40% to 50% of the active ingredient is absorbed from the gastrointestinal tract. While the rate of absorption may be slowed by taking it with food, the total extent of drug absorption is not significantly affected.

Q: How long does Fixim stay in my system after I stop taking it?

A: The mean plasma elimination half-life of the active ingredient is typically reported to be between 3 and 4 hours in adults with normal kidney function. This half-life is the time it takes for the amount of drug in the body to be reduced by half.

Q: Are there different strengths of Fixim available?

A: Yes, Fixim is available in several strengths and formulations. These commonly include 400 mg capsules or tablets, various strengths of chewable tablets, and a powder for oral suspension in multiple concentrations, such as 100 mg/5 mL and 200 mg/5 mL.

Q: Do I need to change my diet while using Fixim?

A: The drug’s absorption is generally not significantly affected by co-administration with food or common antacids. Official regulatory documentation typically does not list general dietary restrictions for the standard patient population.

Q: Can Fixim affect my ability to drive or use machinery?

A: Official documentation states that the active ingredient in Fixim has no known direct influence on the ability to drive or use machines. However, because side effects such as dizziness or headache are documented, it is important to be aware of how these documented effects may impact the ability to drive or operate machinery.

Q: Why is Fixim prescribed for [Disease X, common off-label but established use area]?

A: The medication is indicated for the treatment of specific susceptible bacterial infections. These uses include acute exacerbations of chronic bronchitis, middle ear infections (otitis media), throat and tonsil infections (pharyngitis/tonsillitis), and uncomplicated urinary tract infections.

Q: Is Fixim generally suitable for people over 65?

A: Official guidance states that elderly patients may generally be given the same dose recommended for adults. Given that the drug is primarily eliminated via the kidneys, assessment of renal function is recommended, and dosage adjustments may be necessary for severe kidney impairment.

Q: Is there a generic version of Fixim available?

A: Fixim is a brand name for the active ingredient, cefixime. The active compound is widely available as a generic medication from various manufacturers in the U.S. and internationally.

Q: Can Fixim cause changes in my mood or sleep patterns?

A: Reported effects on the central nervous system include headache and dizziness. While mood or sleep pattern changes are not commonly specified, caution is noted because seizures have been reported with this class of antibiotics, particularly in patients with kidney impairment.

Q: Is Fixim gluten-free, or does it contain common allergens?

A: The 400 mg tablet formulation contains lactose monohydrate as an inactive ingredient. Chewable tablets contain aspartame, which is a source of phenylalanine. The medication is strictly contraindicated for patients with a known allergy to the active ingredient or any other drug in the cephalosporin class.

Q: Is the research evidence for Fixim based mostly on animal or human studies?

A: The evidence base utilized by official health authorities to support its indications is primarily derived from human studies. This includes clinical trials, such as Randomized Controlled Trials (RCTs), and multicenter studies.

Q: Are headaches a common side effect of Fixim?

A: Yes, headaches were reported by 11% of adult patients in clinical trials, classifying them as a frequently reported effect in the official product information.

Q: What if I'm allergic to one of the inactive ingredients in Fixim?

A: The medication is strictly contraindicated only for patients with known hypersensitivity to the active ingredient or any cephalosporin. Inactive ingredients (such as lactose or aspartame) are listed in the official label, and patients with known allergies to any component are advised to review this list with their prescribing physician.

Q: Can I take Fixim if I am lactose intolerant?

A: The 400 mg film-coated tablet formulation contains lactose monohydrate as an inactive ingredient. The presence of lactose in the formulation should be noted by individuals with lactose intolerance for informational purposes.

Q: Does taking Fixim require any special precautions before surgery?

A: Official warnings note that Cefixime may be associated with a decrease in prothrombin activity, a measure of blood clotting. This effect may require monitoring for patients at risk, such as those undergoing or anticipating surgical procedures.

Q: What happens if I start feeling better but still have pills left?

A: As with all antibiotics, regulatory guidance indicates that the full course of therapy should be completed exactly as prescribed, even if symptoms begin to improve or disappear. Stopping the medication too early risks the infection not being completely treated and increases the likelihood of developing drug-resistant bacteria.

Q: Is the shape or color of the Fixim pill meaningful?

A: Official product descriptions detail the appearance of each dosage form for identification purposes. For example, the 400 mg film-coated tablet is officially described as white to off-white, capsule-shaped, and having a score line.

How should Fixim be stored and disposed of?

Storage and Disposal Requirements

Storage conditions for Fixim (cefixime) vary by formulation.


Fixim Tablets and Capsules must be kept at controlled room temperature, generally between 20°C and 25°C. They should be stored in a tightly closed container to protect against moisture.

Fixim Oral Suspension (Reconstituted) must be stored in a refrigerator between 2°C and 8°C. The liquid suspension must not be frozen. Any unused portion of the refrigerated suspension must be discarded after 14 days.

All forms of Fixim must be stored out of the sight and reach of children.

Expired or unused medication should be disposed of via a drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance in a sealed bag and discarded in the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fixim found in:

A-Z Index: